- Home
- MCR vs NTHI Comparison
MCR vs NTHI Comparison
Compare MCR & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCR | NTHI |
|---|---|---|
| Founded | 1989 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.2M | 178.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MCR | NTHI |
|---|---|---|
| Price | $6.06 | $7.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 87.7K | 27.3K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 8.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.57 | $3.20 |
| 52 Week High | $6.57 | $15.50 |
Technical Indicators
Market Signals| Indicator | MCR | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 33.25 |
| Support Level | $6.00 | $6.40 |
| Resistance Level | $6.38 | $7.70 |
| Average True Range (ATR) | 0.08 | 0.73 |
| MACD | -0.00 | -0.14 |
| Stochastic Oscillator | 59.68 | 5.67 |
Price Performance
Historical ComparisonAbout MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).